Mach 1 Financial Group LLC Invests $746,000 in DexCom, Inc. (NASDAQ:DXCM)

Mach 1 Financial Group LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 6,010 shares of the medical device company’s stock, valued at approximately $746,000.

Other hedge funds have also modified their holdings of the company. Sands Capital Management LLC boosted its holdings in DexCom by 4.3% during the 3rd quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company’s stock valued at $1,274,541,000 after acquiring an additional 557,543 shares during the period. Blair William & Co. IL raised its position in DexCom by 1.7% in the 3rd quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company’s stock valued at $420,517,000 after purchasing an additional 73,654 shares in the last quarter. Northern Trust Corp raised its position in DexCom by 2.4% in the 3rd quarter. Northern Trust Corp now owns 3,896,515 shares of the medical device company’s stock valued at $363,545,000 after purchasing an additional 91,249 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in DexCom by 1.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,160,961 shares of the medical device company’s stock valued at $201,618,000 after purchasing an additional 28,621 shares in the last quarter. Finally, Winslow Capital Management LLC acquired a new stake in DexCom in the 3rd quarter valued at about $173,120,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Performance

DXCM traded up $1.58 during trading on Tuesday, hitting $127.39. 3,049,135 shares of the stock were exchanged, compared to its average volume of 3,056,698. The firm has a market capitalization of $50.66 billion, a P/E ratio of 82.19, a PEG ratio of 2.11 and a beta of 1.20. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The stock has a fifty day moving average price of $131.49 and a two-hundred day moving average price of $119.53. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. As a group, sell-side analysts predict that DexCom, Inc. will post 1.78 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on DXCM shares. UBS Group increased their price target on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Canaccord Genuity Group increased their price target on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday. Citigroup increased their price target on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Raymond James increased their price target on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday. Finally, StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Tuesday, April 23rd. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, DexCom presently has an average rating of “Moderate Buy” and a consensus target price of $141.67.

Insiders Place Their Bets

In related news, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares in the company, valued at $5,839,974.37. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CFO Jereme M. Sylvain sold 3,363 shares of DexCom stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares in the company, valued at $8,304,405.66. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the sale, the executive vice president now owns 42,377 shares in the company, valued at $5,839,974.37. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock valued at $25,530,859 over the last quarter. Company insiders own 0.41% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.